Skip to main content

Invitrogen Posts Strong Q2 Revenue Growth, Increased Income

NEW YORK, July 24 - Invitrogen today reported a surge in second-quarter revenue atop increased R&D spending and net loss.

 

For the period ended June 30, Invitrogen said total revenue grew to $192.4 million from $164.3 million year over year. The company attributed 7 percent of the growth to "favorable changes in foreign currency exchange rates."

 

While Invitrogen would not break down dollar figures, the firm said revenue from its cell culture increased 30 percent, while receipts from its molecular-biology products arm increased 10 percent.

 

Second-quarter R&D spending swelled to $12.6 million from $7.7 million in the same period last year. Despite the increased spending - Invitrogen reported $93.3 million in total operating expenses in the second quarter - net income jumped to $16.9 million, or $.34 per share, from $8 million, or $.15 per share, year over year.

 

Invitrogen said it had around $541 million cash and cash equivalents as of June 30.

 

Click here for more information.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.